Can I take Iressa, a targeted drug for lung cancer, in the advanced stage of lung adenocarcinoma? 13621079267 How much does it cost to take Iressa?

[Drug name]
Trade name: Iressa< .
Generic name: Gefitinib tablets
English name: b
[Ingredients] Gefitinib [Indications 】This product is suitable for the treatment of locally advanced or metastatic non-small cell lung cancer that has previously received chemotherapy (). [Usage and Dosage] The recommended dosage is (tablet) once daily, taken on an empty stomach or with food. Not recommended for use in children or adolescents, safety and efficacy have not been studied in this patient population. If you have difficulty swallowing, disperse the tablet in half a glass of drinking water (non-carbonated drinks). No other liquids should be used. Throw the tablet into water without crushing, stir until completely dispersed (it will take about a minute), and drink the liquid immediately. Rinse the cup with half a cup of water and drink. The solution may also be administered via a nasogastric tube.
There is no need to adjust the dosage due to the following conditions: age, weight, gender, race, renal function, moderate to severe liver function impairment caused by liver metastasis.
Dose adjustment: When patients experience intolerable diarrhea or skin adverse reactions, they can be resolved by temporarily suspending treatment (up to a few days), and then resuming the daily dose.
[Adverse Reactions]. The most common adverse drug reactions (R) (with an incidence rate of more than %) are diarrhea and skin reactions (including rash, acne, dry skin and itching), which are generally seen in the first month after taking the drug. Within, usually reversible. Approximately % of patients experienced serious adverse drug reactions (standard or grade). Approximately % of patients discontinued treatment due to R. .Adverse events occurring in each body system are arranged in descending order by frequency (Common: ＞% Common: ＞% and .% and .% and ＜.% Extremely rare: ＜.%) () Based on clinical studies conducted around the world , expanded access/compassionate use and post-marketing use data, interstitial lung disease outside Japan General [Contraindications] Persons with known severe allergic reactions to the active substance or any excipients of this product. [Precautions] Patients receiving gefitinib may occasionally develop acute interstitial lung disease, and some patients may die as a result (see section "Possible Adverse Reactions"). Mortality is increased in patients with concomitant congenital pulmonary fibrosis/interstitial pneumonia/pneumoconiosis/radiation pneumonitis/drug-induced pneumonitis. If the patient's respiratory symptoms such as shortness of breath, cough and fever worsen, treatment should be interrupted and the cause should be identified in time. When interstitial lung disease is confirmed, gefitinib should be discontinued and the patient treated accordingly. Asymptomatic elevations in hepatic transaminases have been observed (see section 'Possible Adverse Reactions'). Therefore, it is recommended to check liver function regularly. It can be used with caution in patients with mild to moderate elevations of hepatic transaminases. If liver function impairment is severe, discontinuation of the drug should be considered. Substances that induce activity [medication for special populations] Precautions for children:
There is currently no data on the safety and efficacy of this product in children or adolescent patients, so its use is not recommended.